...Editor Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available. Unidentified Company Representative 1 It's very similar to our time back in 2017, when our first commercial medicine in Brazil was approved for tardive dyskinesia. I feel that way for a couple of reasons, but let me just start with I think that our past successes has really propelled us to think about the opportunities in the future as a drug discovery and development company commercialization entity we got -- we have three FDA-approved medicines on the market. If we pull out one of those and just talk about aggressive for a moment, as I mentioned, it was approved in 2017, for tardive dyskinesia. There are 600,000 patients in the US today, roughly 80% of those patients are not receiving a VMAT2 inhibitor. This is the mechanism works of valbenazine, two-thirds of patients are not diagnosed. And I start there because in Q2, we reported...
